CONTENTS
CORPORATE PRESENTATION 2014 2
SANOFI AT A GLANCE
OUR GROWTH PLATFORMS
INNOVATION IN R&D
OUR RESPONSIBILITY
KEY FIGURES
CORPORATE PRESENTATION 2014 4
OUR HERITAGE
SANOFI AT A GLANCE
Hoechst Marion
Roussel 1997
Roussel 1911
Marion 1950
Hoechst 1863
Synthélabo 1970
Delalande 1924
Delagrange 1931
Robert & Carrière
1901
Dausse 1834
BMP Sunstone, Medley, Merial, Nepentes, Zentiva,
Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha
Biotechnics 2008-2010
Genzyme 2011
Sanofi-aventis 2004
Aventis 1999
Sanofi-Synthélabo 1999
Sanofi Pasteur 2004
Sterling 1901
Midy 1718
Clin Midy 1971
Chinoin 1919
Sanofi 1973
Connaught 1922
Rorer 1910
Rhône-Poulenc Rorer 1990
Institut Mérieux
1897
Wittman & Poulenc
1860
A long tradition in health
CORPORATE PRESENTATION 2014 5
Information of December 31st 2013
OUR GROUP
SANOFI AT A GLANCE
We are a global
healthcare company
engaged in the
research, development,
manufacturing and
marketing of healthcare
solutions. present in more than
100 countries
more than
110 000 employees
A diversified offer
of pharmaceuticals,
vaccines and innovative
therapeutic solutions
112 Industrial sites in 41 countries
R&D A major biopharmacy
player
• 45% of revenues
generated by biologics
• 80% of development
projects are biologics
€33 bn*
In sales in 2013
* €32,951 M
OUR COMMITMENT AND OUR AMBITION
SANOFI AT A GLANCE
CORPORATE PRESENTATION 2014 6
We act with our partners to protect health,
enhance life, provide hope and respond to
the potential healthcare needs of 7 billion
people around the world.
With our global footprint and commitment
to improving access to medicines
and healthcare, we work tirelessly to
make a difference to people’s lives every
day and transform scientific innovations
into therapeutic solutions for patients.
BRING INNOVATIVE PRODUCTS TO MARKET
SEIZE VALUE-ENHANCING GROWTH OPPORTUNITIES
ADAPT STRUCTURE FOR FUTURE CHALLENGES & OPPORTUNITIES
CORPORATE PRESENTATION 2014 7
DELIVER SUSTAINABLE LONG-TERM GROWTH
SANOFI AT A GLANCE OUR STRATEGY
GROW A GLOBAL HEALTHCARE LEADER WITH SYNERGISTIC PLATFORMS
CORPORATE PRESENTATION 2014 9
OUR GROWTH PLATFORMS
Diabetes solutions
Emerging markets
Vaccines
Consumer Healthcare
Animal Health
Genzyme
Other Innovative Products
OUR GROWTH PLATFORMS
The strong presence of Sanofi in Emerging Markets supports access to health by proposing a wide range of medicines at adapted prices.
EMERGING MARKETS
Latin America Asia Africa & Middle East Eastern Europe Russia Turkey
CORPORATE PRESENTATION 2014 10
(1) IMS Health (IMS Midas 2013)
1st Healthcare Company
in Emerging Markets
in 2013(1)
(1) IMS MIDAS MAT 03/2013
OUR GROWTH PLATFORMS
CORPORATE PRESENTATION 2014 11
DIABETES SOLUTIONS
TODAY Lantus®
#1 worldwide
in insulins(2)
TOMORROW
Source: IDF Diabetes Atlas Sixth Edition,
International Diabetes Federation
By 2030, it is anticipated million people
552
New insulin U300(5) (1)IMS sales 2013
(2)IMS sales 2013
(3)Marketing Authorization granted in Europe February 2013
(4)Launched in India September 2012
(5) U300 is an investigational new formulation of insulin glargine.
Today million people(1)
have diabetes worldwide.
382 Comprehensive
offering of therapies
(3)
(4)
Patient friendly
delivery pens
Intelligent Blood
Glucose Monitoring
devices
Hexaxim®
(in emerging
countries)
CORPORATE PRESENTATION 2014 12
OUR GROWTH PLATFORMS
HUMAN VACCINES
TOMORROW
TODAY
A leadership position with Sanofi Pasteur
1bn doses of vaccines
to immunize more than 500 million
people
infectious diseases
20 vaccines for
A NEW WAVE OF INNOVATION being prepared with vaccines against dengue and infections of Clostridium Difficile (nosocomial infections)
Feminine care: Lactacyd®
CORPORATE PRESENTATION 2014 13
Solutions to manage health in the
everyday life all around the world.
With a diversified brands
portfolio based on consumer
insights-driven innovation.
Pain: Doliprane® No Spa®
Dorflex® Icy Hot®
Gastro-intestinal: Maalox® Rolaids®
Essentiale® Enterogermina®
Allergy: Allegra® Nasacort®
Top 3 Global player in
Consumer Healthcare(1)
(1) IMS MAT Sept 2013,
Nicholas Hall & Company
Cough, cold
and sore throat: Rhinathiol® Bronchicum®
Haowawa®
VMS (vitamins
and mineral
supplements):
Cenovis® Nature’s Own®
Magné Vie®
OUR GROWTH PLATFORMS
CONSUMER HEALTHCARE
World-leading,
innovation-driven
animal health
company, providing
a comprehensive
range of products
to enhance the
health, well-being
and performance
of a wide range of
animals.
CORPORATE PRESENTATION 2014 14
COMPANION ANIMALS
PARVORUVAX Swin
Ruminant
PRODUCTION ANIMALS
Horses
Avian AVINEW
#1 # 2 companion
animal
avian
vaccines
Dogs&Cats
OUR GROWTH PLATFORMS
ANIMAL HEALTH: MERIAL
Gaucher disease
Pompe disease
Fabry disease
CORPORATE PRESENTATION 2014 15
OUR GROWTH PLATFORMS
GENZYME: RARE DISEASES AND MULTIPLE SCLEROSIS
TODAY
RARE DISEASES RARE DISEASES
TOMORROW
MULTIPLE SCLEROSIS
7,000 rare diseases identified
worldwide of which
400 have a treatment
Gaucher disease
Homozygous familial
Hypercholesterolemia
Mucopolysaccharidosis
Type I
Colorectal cancer
OTHER INNOVATIVE PRODUCTS
OUR GROWTH PLATFORMS
CORPORATE PRESENTATION 2014 16
Atrial fibrillation
ANTIARRYTHMIC
Hematopoietic cancer
Prostate cancer
ONCOLOGY
ALLERGY
• Multiple Sclerosis
• Diabetes
• Oncology
• Rare Diseases
• Cardio-Metabolic Diseases
• Immunology
• Vaccines
CORPORATE PRESENTATION 2014 18
We have to be where the diseases and the patients’ needs are.
We act as one to discover and develop therapies that prevent, treat and cure disease.
9
projects and vaccines in clinical development
high potential projects in late
stage development
49
INNOVATION IN R&D
ACCELERATE INNOVATION FOR PATIENTS
Our main areas of research include:
CORPORATE PRESENTATION 2014 19
This health ecosystem places the patient and their needs at the heart of the priorities.
Translational Medicine to create deeper interaction between clinic and fundamental research and improve diagnosis and patient care.
INNOVATION IN R&D
ACCELERATE INNOVATION FOR PATIENTS
Open innovation
VENTURE CAPITAL
HOSPITALS
GOVERNMENT BIOPHARMA
PATIENTS
PATIENTS
NEEDS
UNIVERSITIES
TECH
Biotechnology partnerships to accelerate innovation.
80% of our development
projects are biologics(1)
(1) 39 new molecular entities and vaccines of a total of 49 (source: Sanofi annual results 2013)
20
Diabetes • U300
• Lixisenatide
• LixiLan
Atopic dermatitis
and asthma
• Dupilumab
• Alirocumab
Hypercholesterolemia
• Sarilumab
Rheumatoid arthritis
INNOVATION IN R&D
STRENGTHENED
AND INNOVATIVE
PORTFOLIO FOR
PATIENTS
Human Vaccines • 6-in-1 vaccine PR51
• Dengue vaccine
• Clostridum Difficile vaccine
Product launches
between
2014 and 2018
High potential 9
(source: Sanofi annual results 2013)
CORPORATE PRESENTATION 2014 20
Improve access to medicines by promoting
comprehensive management of diseases
combining prevention, diagnosis and treatment
in developing countries.
reduce health inequalities
through its ’programs dedicated to:
Childhood Cancer, Maternal and Neonatal Mortality
and access to healthcare for the world’s poorest
populations.
Promoting quality care by fighting against
counterfeit medicines.
More than
1/3 of the population
have no access
to healthcare.
CORPORATE PRESENTATION 2014 22
OUR RESPONSIBILITY
ACCESS TO QUALITY HEALTHCARE FOR ALL
To “move further” the human
right to health becomes
a reality, Sanofi develops
programs to improve access
to medicines for people
in developing countries.
The main
disease areas
for Access
to Medicines
CORPORATE PRESENTATION 2014 23
Approach • Information and education
• Medicines adapted to patients needs
• Tiered pricing policy
• R&D program for therapeutic innovation
• Industrial expertise
OUR RESPONSIBILITY
IMPROVE ACCESS TO MEDICINES
•Malaria •Tuberculosis •Neglected Tropical Diseases (Sleeping
sickness, Leishmaniasis…)
•Mental health •Epilepsy
and vaccine Preventable diseases
years partnership with WHO in the fight against Neglected Tropical diseases
10
CORPORATE PRESENTATION 2014 24
NEGLECTED TROPICAL DISEASES
A genuine partner to fight and eliminate sleeping sickness by 2020.
OUR RESPONSIBILITY
IMPROVE ACCESS TO MEDICINES
WHO – February 2014
patients treated
175,000 Acting
ethically and
responsibly is part of our DNA
people were screened
27million
More than
SLEEPING SICKNESS
Access to healthcare for excluded populations
PRECARITY AND HEALTH
Ease and improve access
to healthcare for socially
excluded populations
in France through
a partnership with the Red
Cross, Médecins du Monde
and the Samu Social.
CORPORATE PRESENTATION 2014 25
Maternal and infant mortality
STAND UP FOR AFRICAN MOTHERS
Initiated in 2010
in partnership with
the African Medical
& REsearch Foundation
(AMREF).
Today, 5 000 midwives
trained.
Childhood cancers in developing countries
MY CHILD MATTERS
45 projects in 33 countries in
Asia, Africa and Latin
America in partnership with
UICC (Union for International
Cancer Control)
OUR RESPONSIBILITY
REDUCING HEALTH INEQUALITIES
Sanofi’s commitment to protecting the safety of patients by fighting counterfeit medicines.
PROMOTE QUALITY HEALTHCARE
OUR RESPONSIBILITY
CORPORATE PRESENTATION 2014 26
Laboratory dedicated to the analysis of counterfeit products
Sanofi mobile app for travelers on the dangers of counterfeit medicines.
https://itunes.apple.com/us/app/travel-tips-against-counterfeit/id771218216
products have been analysed
20,000
Supports market surveillance
* Since 2008
*
Apple, the Apple logo, iPad and iPhone are trademarks ofApple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
Other countries
3,730 Emerging markets
10,957
United States
10,433
Western Europe
7,831
TOTAL SALES BY GEOGRAPHICAL ZONE (in million euros)
DETAIL OF GROWTH PLATFORMS (in million euros)
(Growth at constant exchange rates)
CORPORATE PRESENTATION 2014 28
Emerging Markets €10,957M
Diabetes Solutions € 6,568M
Vaccines € 3,716M
Consumer Healthcare € 3,004M
Genzyme € 2,142M
Animal Health € 1,985M
Other Innovative Products € 705M
KEY FIGURES 2013
€32,951M
Information of December 31st 2013
NET SALES (in million euros)
Our global workforce: more than 110,000 employees throughout the World
KEY FIGURES 2013
CORPORATE PRESENTATION 2014 29
EMPLOYEES BY GEOGRAPHIC ZONE
Other countries
39,000
Europe
54,000
North America
18,000
Information of December 31st 2013
CORPORATE PRESENTATION 2014 30
82 sites pharmaceuticals
12 sites vaccines
17 sites animal health
* Information of December 31st 2013
112 Industrial sites*
in 41 countries, of which 37 are emerging countries
in Europe
in North America
in Asia
More than
20
R&D sites worldwide
PRESENT IN MORE THAN 100 COUNTRIES
KEY FIGURES 2013
CORPORATE PRESENTATION 2014 32
SANOFI INDIA AT A GLANCE
DIVERSIFIED OFFERING
PRODUCTS
MANUFACTURING
CORPORATE SOCIAL RESPONSIBILITY
WORKING AT SANOFI
CONTENTS
CORPORATE PRESENTATION 2014 33
OUR GROUP
SANOFI AT A GLANCE
Since 1956, Sanofi
has aligned itself with
India’s healthcare
needs by building
expertise, capability &
capacity, through continued
investments, strategic
partnerships, and a
shared commitment
towards patients.
exports to more than
30 countries
more than
5000 employees
3 state-of-the-art
manufacturing
sites
Operates through
5 legal entities
A
diversified
offering in Diabetes, Vaccines,
CHC, Animal Health
and innovative
therapeutic solutions
Present in India
since
1956 Evolved from Hoechst …
Aventis… sanofi-
aventis… to finally
Sanofi
through M&As
AT A GLANCE
SANOFI INDIA
OFFERS
THERAPEUTIC
SOLUTIONS
ACROSS…
ANTI-
INFECTIVES
NEPHROLOGY
VACCINES BIOSURGERY
ANIMAL
HEALTH
DIABETES
CARDIOVASCULAR
DISEASES
CENTRAL
NERVOUS SYSTEM
ONCOLOGY
CONSUMER
HEALTHCARE
MASS
THERAPY
RARE
DISEASES THROMBOSIS
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
DIVERSIFIED
OFFERING
SANOFI INDIA
34
OFFERS
THERAPEUTIC
SOLUTIONS
ACROSS…
ANTI-
INFECTIVES
NEPHROLOGY
VACCINES
BIOSURGERY
ANIMAL
HEALTH
DIABETES
CARDIOVASCULAR
DISEASES
CENTRAL
NERVOUS SYSTEM
ONCOLOGY CONSUMER
HEALTHCARE
MASS
THERAPY
RARE
DISEASES
THROMBOSIS
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
Sanofi Pasteur (the vaccines division of
Sanofi) offers protection
against
15 infectious
diseases
Genzyme – A Sanofi company:
Provides hope to Indian
patients with Rare
Diseases and creates
sustainable access
Consumer
Healthcare - an ensemble of more than
50 brands such as Seacod,
Combiflam, Primosa,
and Freeflex
Saath 7 Longest running
diabetes patient
support program
AllStar™ Indigenously
developed reusable
insulin pen specially
designed for Indian
patients
Diabetes
Merial creating a
healthier world
for animals
DIVERSIFIED
OFFERING
SANOFI INDIA
34
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
PRODUCTS
SANOFI INDIA Our top
10
brands*
*Source : IMS TSA Jan 2014
35
Group
Group
Group
Group
Group
Pharmaceuticals & Vaccines
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
MANUFACTURING
SANOFI INDIA
37
3 state-of-the-art
manufacturing sites
Ankleshwar
• Active Pharma
Ingredients (API)
• Formulations
Goa
• Formulation
production
• Formulation
development
Hyderabad
Vaccines
In 2013, manufactured…
8.5 bn units of
tablets and
capsules
145 mn units of vials
and
ampoules
34 mn units of
creams and
ointments
20 mn units of
liquids
For Domestic use
APIs, intermediates, granules,
bulk tablets and finished formulations
For exports
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
MANUFACTURING
SANOFI INDIA
38
Running Manufacturing
operations in India since
the last
54 years
India Manufacturing strengths
Technical experience
Ankleshwar
approved by
USFDA & AFFSAPS
Goa
approved by
European,
Australian, and
Brazilian regulatory
Facilities & systems
Production of API
Large volume
manufacturing
of formulations at own
sites
Effectively
managing huge
volumes
from external sites
Exports to 33
countries
Diverse expertise
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
CSR
SANOFI INDIA
39
OUR SUSTAINABILITY
APPROACH places the
patient at the ‘heart’ of
the way we conduct our
business.
OUR STRATEGY HAS
FOUR KEY AREAS:
Patient, Ethics, People
and Planet.
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
CSR
ACTIVITIES
SANOFI INDIA
40
REDUCING MATERNAL MORTALITY
Employees volunteer for
OPPI’s initiative to help
reduce Maternal Mortality in
India.
The employees have
participated in heath check-
up camps and have
reached out to more than
1000 mothers till date.
GYAN EXPRESS
An initiative to mentor
underprivileged children
in Mumbai, in association
with Concern India
Foundation.
Mentored 50 children from
4 NGOs in Mumbai over a
period of two months.
Employee volunteering
FUN CENTERS
Recreation zones,
created especially to
comfort and support the
little ones, as they cope
with the rigours of long
term treatment and
hospitalization
Sanofi ‘Fun Centers have
benefitted more than
30,000 children in 5
hospitals.
Patients
CSR
ACTIVITIES
SANOFI INDIA
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
CSR
ACTIVITIES
SANOFI INDIA
41
Health camps in schools
in partnership with the
Voluntary Health
Association of Goa
(VHAG).
8000 children monitored
and counselled through
these health camps, since
2012.
VHAG SEWA Rural
Blood sugar level testing
of the local community at
SEWA Rural hospital in
Ankleshwar.
More than 6,000 patients
benefitted from this service
since its launch in 2012.
Reducing health inequalities around sites
WINDMILL
A 2.1 MW offsite
windmill installed to
generate renewable
power at the Ankleshwar
manufacturing site,
through an agreement
with India’s largest wind
turbine manufacturer –
Suzlon Energy Limited
(SEL).
Planet
CSR
ACTIVITIES
SANOFI INDIA
CORPORATE PRESENTATION 2014
OUR GROUP
SANOFI AT A GLANCE
DIVERSIFIED
OFFERING
SANOFI INDIA
WORKING AT
SANOFI
SANOFI INDIA
42
Acquire skills
and create
opportunities
Immense scope to
develop and
expand skill-sets
Take pride in
contributing to
world health
Strive for
excellence
to improve the
health of patients
around the world
Work with
committed
professionals
An environment
of mutual respect
where people
enjoy collaborating
and learning
from each other
AT SANOFI, OUR EMPLOYEES…
Ethics & Compliance Hallmark of everything we do